Table 1.
Patient Characteristics of NMEDW dataset.
| All patients | SARS-CoV-2 positive patients | |||
|---|---|---|---|---|
| Carvedilol− | Carvedilol+ | Carvedilol− | Carvedilol+ | |
| Total | 478,536 | 2,990 | 66,289 | 252 |
| Age | 44.67 ± 21.74 | 67.37 ± 15.08 | 41.86 ± 21.09 | 63.52 ± 17.20 |
| Sex, male | 202,994 (42.4) | 1,674 (56.0) | 30,550 (46.1) | 146 (57.9) |
| Race | ||||
| Black | 41,858 (8.7) | 725 (24.2) | 6,136 (9.3) | 73 (29.0) |
| White | 343,549 (71.8) | 1,927 (64.4) | 46,493 (70.1) | 143 (56.7) |
| Other | 60,273 (12.6) | 274 (9.2) | 9,407 (14.2) | 27 (10.7) |
| Comorbidity | ||||
| AIDS HIV | 1,843 (0.4) | 36 (1.2) | 248 (0.4) | 5 (2.0) |
| CD | 32,555 (6.8) | 1,336 (44.7) | 3,498 (5.3) | 103 (40.9) |
| CPD | 87,868 (18.4) | 1,249 (41.8) | 12,078 (18.2) | 123 (48.8) |
| CHF | 26,973 (5.6) | 2,042 (68.3) | 3,331 (5.0) | 172 (68.3) |
| Dementia | 8,567 (1.8) | 358 (12.0) | 1,297 (2.0) | 42 (16.7) |
| Diabetes w cc | 20,670 (4.3) | 1,359 (45.5) | 3,031 (4.6) | 139 (55.2) |
| Diabetes wo cc | 54,322 (11.4) | 1,629 (54.5) | 8,301 (12.5) | 150 (59.5) |
| HP | 5,380 (1.1) | 298 (10.0) | 568 (0.9) | 27 (10.7) |
| Malignancy | 47,660 (10.0) | 805 (26.9) | 4,606 (6.9) | 67 (26.6) |
| MST | 23,690 (5.0) | 413 (13.8) | 2,385 (3.6) | 36 (14.3) |
| MLD | 29,730 (6.2) | 583 (19.5) | 3,711 (5.6) | 53 (21.0) |
| MSLD | 2,906 (0.6) | 119 (4.0) | 307 (0.5) | 11 (4.4) |
| MI | 7,913 (1.7) | 630 (21.1) | 1,017 (1.5) | 54 (21.4) |
| PUD | 11,785 (2.5) | 309 (10.3) | 1,289 (1.9) | 32 (12.7) |
| PVD | 23,925 (5.0) | 1,158 (38.7) | 2,626 (4.0) | 99 (39.3) |
| RD | 26,068 (5.4) | 1,820 (60.9) | 3,479 (5.2) | 181 (71.8) |
| RhD | 13,887 (2.9) | 232 (7.8) | 1,607 (2.4) | 18 (7.1) |
Age is shown as mean ± standard deviation. All other characteristics are shown as number of cases (percentage). P values were calculated by two-sided t test for age and Fisher’s exact test for other variables. AIDS HIV, acquired immunodeficiency syndrome and human immunodeficiency virus; CD, cerebrovascular disease; CPD, chronic pulmonary disease; CHF, congestive heart failure; Diabetes w/wo cc, diabetes with/without chronic complications; HP, hemiplegia or paraplegia; MST, metastatic solid tumor; MLD, mild liver disease; MSLD, moderate or severe liver disease; MI, myocardial infarction; PUD, peptic ulcer disease; PVD, peripheral vascular disease; RD, renal disease; RhD, rheumatic disease.